ACE-inhibitors in Extracapillary Glomerulonephritis
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The natural course of extracapillary glomerulonephritis is severe leading to End-Stage Renal
Disease (ESRD) or death in most cases. Despite immunosuppressive treatment, long-term renal
outcome remains poor since active crescents usually progress to fibrotic scars with
glomerular occlusion and disruption.In experimental models Angiotensin Converting Enzyme
(ACE)-inhibitor therapy targeting the over-expression of angiotensin type 1 (AT1) receptors,
that are responsible for dysregulated proliferation of parietal cell progenitors, blocks the
formation of crescents and their fibrotic evolution. Should these drugs have similar effects
in humans, ACE-inhibitor therapy on top of standard immunosuppression might be instrumental
to prevent ESRD and promote renal function recovery in clinical practice.